



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 11, 2021

Rick Pauls  
President and Chief Executive Officer  
DiaMedica Therapeutics Inc.  
Two Carlson Parkway, Suite 260  
Minneapolis, Minnesota 55447

**Re: DiaMedica Therapeutics Inc.  
Registration Statement on Form S-3  
Filed March 10, 2021  
File No. 333-254089**

Dear Mr. Pauls:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dillon Hagius at 202-551-7976 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Amy Culbert